Pioneering Oral Integrin Medicines
Leveraging decades of integrin expertise to transform treatment paradigms for patients
Our Lead Candidate, MORF-057
A highly specific, orally-available inhibitor of α4β7 in Phase 2 for IBD
A Pipeline spanning multiple therapeutic areas
Drugging both novel and highly validated targets in multiple autoimmune, fibrosis diseases, and cancer.
Join our team
We have fostered a culture of scientific rigor and camaraderie. Be a game changer with the Morphic team.